Comparison of Linezolid and Vancomycin in the Treatment of Ventilator-associated Pneumonia Induced by MRSA

OBJECTIVE:To compare the efficacy and safety of linezolid vs.vancomycin in the treatment of MRSA-inducing ventilator-associated pneumonia in ICU.METHODS:In randomized controlled trials,54 patients with MRSA-inducing ventilator-associated pneumonia in ICU were randomly divided into 2 groups.Linezolid group (n=24) were administered with linezolid 600 mg every 12 h for 10 days,ivgtt.Vancomycin group (n=30) were given vancomycin 500 mg every 8h for 10 days ivgtt.Adverse events and the efficacy of two groups were investigated.RESULTS:Comparison results of linezolid group vs.vancomycin group were as follows:effective rates:100% vs.66.7%,MRSA eradication rates:87.5% vs.43.3%,adverse reactions rates:12.5% vs.13.3%.There were significant differences in the effective rates and MRSA eradication rates between two groups.CONCLUSION:The efficacy and safety of linezolid in the treatment of MRSA-inducing ventilator-associated pneumonia is superior to vancomycin.